Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $7,462,863.00 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.41, for a total value of $47,738.99.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $25.74 on Friday. Hims & Hers Health, Inc. has a 52 week low of $8.14 and a 52 week high of $35.02. The stock has a market capitalization of $5.62 billion, a P/E ratio of 58.50 and a beta of 1.31. The stock has a fifty day moving average of $27.11 and a 200-day moving average of $21.62.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the company earned ($0.04) earnings per share. The company’s revenue was up 77.1% on a year-over-year basis. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp bought a new stake in Hims & Hers Health in the second quarter valued at about $111,000. Finally, Quarry LP lifted its stake in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares during the period. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on HIMS. Needham & Company LLC boosted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday. They issued a “buy” rating and a $35.00 target price on the stock. Piper Sandler increased their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.80.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.